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Mitochondrial disorders are among the most severemetabolic disorders wherein patients suffer from
multisystemic phenotypes, often resulting in early death.1
Clinical, biochemical, and genetic heterogeneity among
individuals, together with poor understanding of gene-to-
phenotype relationships, pose significant diagnostic and
therapeutic challenges for clinicians. In light of recent
advances in next generation sequencing technologies,
whole exome sequencing (WES) is emerging as the new
global standard for the diagnosis of monogenic disorders,
including mitochondrial diseases.2 However, owing to
genetic heterogeneity of mitochondrial disorders and
ongoing discovery of novel disease genes, WES data may
not provide clinicians with enough certainty for a defini-
tive diagnosis.
With these challenges in mind, we present the
Leigh Map, a novel computational gene-to-phenotype
network to be used as a diagnostic resource for mito-
chondrial disease, using Leigh syndrome (Mendelian
Inheritance in Man 256000), the most genetically hetero-
geneous and most frequent phenotype of pediatric mito-
chondrial disease,3,4 as a prototype. Leigh syndrome is a
progressive neurodegenerative disorder defined neuropa-
thologically by spongiform basal ganglia and brainstem
lesions.4,5 Clinical manifestations include psychomotor
retardation, with regression, and progressive neurological
abnormalities related to basal ganglia and/or brainstem
dysfunction, often resulting in death within 2 years of
initial presentation.4,6 However, many patients may also
present with multisystemic (eg, cardiac, hepatic, renal, or
hematological) phenotypes. To date, there are 89 genes
known to cause Leigh syndrome, the majority of which
are difficult to definitively differentiate from each other,
either biochemically or clinically. We hypothesized that
these multisystemic features may help to distinguish dif-
ferent genetic subtypes of Leigh syndrome.
The Leigh Map (freely available at vmh.uni.lu/
#leighmap), was built on the Molecular Interaction NEt-
woRks VisuAlization (MINERVA) platform7 previously
used to construct networks of Parkinson disease and
human metabolism.8–10 The network comprises 89 genes
and 236 phenotypes, expressed in Human Phenotypic
Ontology (HPO) terms,11,12 providing sufficient pheno-
typic and genetic variation to test the network’s diagnos-
tic capability. The Leigh Map aims to enhance the
interpretation of WES data to aid clinicians in providing
faster and more accurate diagnoses for patients so that
appropriate measures can be taken for optimal manage-
ment. The phenotypic components of the Leigh Map
can be queried to generate a list of candidate genes. In
addition, the genetic components of the Leigh Map may
also be queried to browse a list of all reported pheno-
types associated with a particular gene defect. We pro-
pose that this functionality can be used to enhance
clinical surveillance of patients with an established genet-
ic diagnosis. Blinded validation of test cases containing
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clinical and biochemical, but not genetic, data demon-
strated that 2 independent testers were able to predict
the correct causative gene using this method in 80% of
cases. The success of the Leigh Map demonstrates the
efficacy of computational networks as diagnostic aids for
mitochondrial disease (Fig 1).
Creation of the Leigh Map
Systematic Literature Review
The genetic and phenotypic information gathered in this
study came from an initial knowledgebase of >900 pub-
lications, collected from PubMed (latest search November
2016) and the senior author’s personal archive. To facili-
tate data collection from this large breadth of literature
associated with Leigh syndrome, we performed systematic
literature mining with QDA Miner Lite (v1.4.2; Provalis
Research, Montreal, Quebec, Canada) to generate a list
of genes reported to cause Leigh syndrome or Leigh-like
syndromes, and their corresponding phenotypes. Pheno-
typic information was standardized by manually entering
each reported phenotype into Phenomizer (compbio.-
charite.de/phenomizer),11,12 a free online resource, which
catalogues thousands of standardized human phenotypes,
to obtain the appropriate HPO term and number. In
addition to obtaining individual Leigh syndrome genes
and phenotypes, we collected information on additional
parameters that will give users further insight for an
informed diagnosis. Such parameters include modes of
inheritance, magnetic resonance imaging findings, and
patient demographic information. These data were then
organized into an Excel file. Although we aimed to rely
solely on text mining to obtain these data, some publica-
tions required manual clarification, owing to formatting
errors on QDA Miner, which were especially prevalent in
publications with large tables. In total, we consulted
>500 publications to create the Leigh Map. A simplified
version of the gene-to-phenotype knowledgebase is pro-
vided in Tables 1 and 2.
Structure and Functionality of Leigh Map
The Leigh Map was manually assembled using CellDe-
signer (v4.4)13 by incorporating phenotypic, genetic, and
demographic data collected through literature mining.
The map layout loosely follows mitochondrial structure.
The outermost compartment represents the cytosol,
where it is possible to find the nucleus and the mito-
chondrion. Three nuclear genes, nuclear envelope protein
NUP62, nuclear export protein RANBP2, and adenosine
deaminase ADAR, have been included in our network as
genes causing a clinical and radiological phenotype close-
ly resembling Leigh syndrome.14–16 The mitochondrion
is visualized in its double membrane structure, and mito-
chondrial genes are grouped according to function and
can be found in their submitochondrial location (eg, out-
er membrane, matrix). To represent gene-to-phenotype
associations, a submap was created for each gene, display-
ing all phenotypes associated with any given gene defect.
Also incorporated at this stage are links to external data-
bases (eg, Uniprot17 and HGNC18) and modes of inheri-
tance. This approach enables a modular overview of the
map, avoiding overwhelming the user with the “hairball”
effect caused by the high connectivity of the network. All
FIGURE 1: Conceptualization of the Leigh Map. The Leigh Map is a novel computational resource that effectively integrates a
large amount of phenotypic and genetic data from the literature and synthesizes it into a comprehensive resource that has the
potential to improve diagnostic outcomes and more vigilant clinical surveillance for patients with Leigh syndrome. WES5
whole exome sequencing.
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TABLE 1. Leigh Syndrome Disease Genes and Phenotypes Associated with Metabolism
Mitochondrial Dysfunction Genes (mode of inheritance) Example Phenotypes
OXPHOS subunits
Complex I NDUFA1 (XL); NDUFA2, NDUFA9,
NDUFA10, NDUFA12, NDUFS1,
NDUFS2, NDUFS3, NDUFS4,
NDUFS7, NDUFS8, NDUFV1,
NDUFV2 (AR); MT-ND1,
MT-ND2, MT-ND3,
MT-ND4, MT-ND5, MT-MD6
(maternal)
DDwR, FTT, hypertrichosis, HCM,
LA, LD, liver failure, myopathy, OA,
PN, renal tubulopathy, SNHL, SZ
Complex II SDHA (AR) DDwR, FTT, HCM, LA, OA, paraganglioma,
pheochromocytoma, SZ
Complex III UQCRQ (AR) Ataxia, dementia, DD, dystonia, myopathy
Complex IV COX8A, NDUFA4 (AR);
MT-CO3 (maternal)
Ataxia, DD, DR, diabetes mellitus, LA, LD,
microcephaly, PN, SNHL, SZ
Complex V MT-ATP6 (maternal) DDwR, FTT, HCM, LA, LD, myopathy,
OA, SZ
OXPHOS assembly
Complex I assembly NDUFAF2, NDUFAF4, NDUFAF5,
NDUFAF6, C17ORF89, FOXRED1,
NUBPL (AR)
Anemia, DDwR, FTT, HCM, LA, liver failure,
myopathy, OA, SNHL, SZ
Complex II assembly SDHAF1 (AR) DDwR, LA, LD, liver failure, myopathy
Complex III assembly BCS1L, TTC19 (AR) DDwR, FTT, LD, LA, liver failure, renal tubul-
opathy, SNHL, SZ
Complex IV assembly SURF1, SCO2, COX10, COX15,
PET100 (AR)
DDwR, FTT, hypertrichosis, HCM, LA, LD,
myopathy, OA, renal tubulopathy, SNHL, SZ
Cofactor biosynthesis and
metabolism
CoQ10 biosynthesis COQ9, PDSS2 (AR) DDwR, FTT, HCM, hypotonia, myopathy,
nephrotic syndrome, renal tubulopathy, SZ
Lipoic acid biosynthesis LIAS, LIPT1 (AR) DDwR, dystonia, FTT, hypertension, LA, LD,
OA, SZ
Thiamine metabolism SLC19A3, TPK1 (AR) DDwR, dystonia, microcephaly, hypoglycemia,
LD, OA, SZ
Biotinidase BTD (AR) Ataxia, DR, hypotonia, LA, spastic tetraplegia
Other metabolic dysfunction
Pyruvate dehydrogenase complex PDHA1 (XL); PDHX, PDHB,
DLAT, DLD (AR)
DD, FTT, LA, LD, microcephaly, myopathy,
OA, PN, SZ
Amino acid metabolism HIBCH, ECHS1 (AR) Abnormal plasma acylcarnitines, DDwR, FTT,
LA, LD, microcephaly, myopathy, OA, SZ
AR5 autosomal recessive; DD5 developmental delay; DDwR5 developmental delay with regression; DR5 developmental regression; FTT5 fai-
lure to thrive; HCM5 hypertrophic cardiomyopathy; LA5 lactic acidosis; LD5 leukodystrophy; OA5 optic atrophy; OXPHOS5 oxidative phos-
phorylation; PN5 peripheral neuropathy; SNHL5 sensorineural hearing loss; SZ5 seizures; XL5X-linked.
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submaps were integrated in the MINERVA framework,7
which makes use of the Google Maps application pro-
gramming interface, enables content query, and allows a
low-latency interactive navigation of the network and its
submodules simply by clicking a specific gene and open-
ing the embedded submap window available on the
interface.
Navigation through the network is similar to that
of Google Maps, wherein the user can reveal increas-
ingly specific components of information by zooming
in on the different compartments (Fig 2, Supplementa-
ry Figs 1–4). Additional data (patient demographics,
modes of inheritance, external annotations, etc) can be
accessed by clicking an element of the map. The corre-
sponding data will be displayed in the left panel. The
search functionality enables the query of multiple genes
and phenotypes. The query results are displayed in the
information panel and are also highlighted on the
map. When searching for multiple phenotypes, all
genes associated with each phenotype will be listed.
Opening the submap for any given gene will display 1
or more of the highlighted phenotype elements, pro-
viding an immediate visual interpretation of the search
results.
TABLE 2. Leigh Syndrome Disease Genes and Phenotypes Associated with Other Mitochondrial Functions
Mitochondrial Dysfunction Genes (mode of inheritance) Example Phenotypes
Mitochondrial DNA maintenance POLG, SUCLA2, SUCLG1,
FBXL4 (AR)
DDwR, FTT, HCM, LA, LD,
methylmalonic aciduria, myopa-
thy, OA, renal tubulopathy, SZ
Mitochondrial translation GFM1, GFM2, TSFM, TRMU, MTFMT,
GTPBP3, TACO1, C12ORF65, LRPPRC,
EARS2, FARS2, IARS2, NARS2 (AR);
MT-TI, MT-TK, MT-TL1,
MT-TL2, MT-TV, MT-TW (maternal)
Anemia, DDwR, FTT, hypogly-
cemia, HCM, LA, LD, OA,
renal tubulopathy, SZ
Mitochondrial dynamics SLC25A46 (AR), DNM1L (AD) Ataxia, DDwR, FTT, hypotonia,
microcephaly, LA, SZ
Mitochondrial import SLC25A19 (AR) DD, FTT, hypotonia, micro-
cephaly, PN, SZ
Membrane phospholipids SERAC1 (AR) 3-Methylglutaconic aciduria,
DDwR, FTT, LA, liver failure,
OA, SNHL, SZ
Mitochondrial sulfur dioxygenase ETHE1 (AR) DDwR, ethylmalonic aciduria,
LA, renal tubulopathy, SZ
Oligomeric AAA1ATPase CLPB (AR) DDwR, FTT, HCM, LD, OA,
SZ
Apoptosis AIFM1 (AR) DDwR, HCM, hypoglycemia,
SNHL, SZ
RNA import PNPT1 (AR) DR, dystonia, muscle weakness,
SNHL, SZ
RNA-specific adenosine deaminase ADAR (AR) DDwR, microcephaly, SZ, skin
hyperpigmentation
Nuclear translocation pathway RANBP2 (AR) Ataxia, cognitive impairment,
myopathy, SZ
Nuclear pore complex protein NUP62 (AR) FTT, DR, OA, SZ
Manganese transporter SLC39A8 (AR) DD, FTT, LA, SNHL, SZ
AD5 autosomal dominant; AR5 autosomal recessive; ATPase5 adenosine triphosphatase; DD5 developmental delay; DDwR5 developmental
delay with regression; DR5 developmental regression; FTT5 failure to thrive; HCM5 hypertrophic cardiomyopathy; LA5 lactic acidosis;
LD5 leukodystrophy; OA5 optic atrophy; PN5 peripheral neuropathy; SNHL5 sensorineural hearing loss; SZ5 seizures.
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The Leigh Map provides data about 89 genes
reported to cause Leigh syndrome and Leigh-like syn-
dromes, the highest number of Leigh syndrome genes
that has been collated to date, as well as 236 associated
phenotypes. The network consists of >1,700 interactions,
all of which can be manually queried by the user. To facili-
tate access, causative Leigh syndrome genes are segregated
according to gene function and arranged on a simplified
schematic of the mitochondrion. Genes with similar func-
tions are grouped together in subcategories. Examples of
gene categories that can be found on the Leigh Map
include genes involved in oxidative phosphorylation (eg,
NDUFA1, SDHA) and genes that maintain mitochondrial
DNA (eg, POLG, SUCLA2; see Fig 2). Expression of
Leigh syndrome phenotypes in HPO terms11,12 serves to
normalize the network, thereby eliminating discrepancies
in clinical jargon for phenotypes for which >1 synonym
exists. “Leukodystrophy,” for example, can be described
alternatively as “leukoencephalopathy” or “white matter
changes.” The use of different nomenclature varies among
clinicians and in different geographical regions; therefore,
the use of a single HPO term (leukodystrophy; HP:
0002415) simplifies the Leigh Map and encourages its
widespread utilization (Fig 3).
FIGURE 2: Schematic layout of the Leigh Map. The Leigh Map is a novel gene-to-phenotype network that can be used as a
diagnostic resource for Leigh syndrome. The layout and navigation of the Leigh Map are similar to those of Google Maps,
wherein the user zooms in on components to reveal further layers of information. (A) The outermost part of the Leigh Map
is a simplified diagram of the cell. (B, C) Clicking on a compartment (eg, the mitochondrion) reveals categories of genes
associated with Leigh syndrome (B), and zooming in on subcompartments within the mitochondrion reveals individual
genes (C). (D) Detailed information about a specific gene defect can be accessed by clicking on a gene (SURF1 in this exam-
ple), which will display a left-hand panel that provides additional information and external annotations. (E) Each gene con-
tains a "submodel" that can be accessed by clicking. Gene submodels display all phenotypes associated with the gene of
interest (a total of 96 phenotypes in the case of SURF1 deficiency). Live screenshots of the Leigh Map are provided in Sup-
plementary Figure 1.
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The Efficacy of the Leigh Map as a Diagnostic
Resource
Blinded validation by 2 nonclinical investigators using
a series of anonymized test cases revealed that the Leigh
Map was able to identify the correct gene for 16 of 20
cases. The first and second authors, who both lack for-
mal clinical expertise, acted as independent blinded
testers of the network. The anonymized test cases were
obtained from the senior author’s clinical practice, a
national mitochondrial disease clinic where patients
with Leigh syndrome who have diverse clinical presen-
tations and genetic causes are diagnosed and managed.
The criteria for these test cases were patients who had a
definitive genetic diagnosis of Leigh syndrome, con-
firmed by Sanger sequencing or WES. Testers were pro-
vided with clinical vignettes and biochemical data,
without genetic information. All corresponding pheno-
types identified from each test case were entered into
the query box of the Leigh Map, each separated by a
semicolon. The search tool then generated a list of
candidate genes for each phenotype in individual pan-
els, which were then manually browsed to establish a
list of candidate genes (see Fig 3). We define "candidate
genes" as those that include >50% of the queried phe-
notypes. Due to the immense number of phenotypes
on the network, every test case generated a list of
potentially causative genes. For 10 cases, the Leigh
Map was able to identify the correct gene as the "top
hit," that is, the gene corresponding to the highest
number of matched phenotypes. The network also pre-
dicted the correct gene for an additional 6 cases, in
which they were not the top hit. In the remaining 4
test cases, the Leigh Map failed to produce the correct
gene as one of the generated candidate genes. In all
cases, the Leigh Map produced a shortlist of no more
than 8 candidate genes, effectively eliminating 90%
of the genes in the network. Multiple advanced search
is not yet possible on this platform, so some manual
deduction is required for the use of the Leigh Map at
this time.
FIGURE 3: Querying the Leigh Map. (A–C) All phenotypic and genetic components of the Leigh Map can be queried using the
search function in the left-hand panel. The user can query a particular gene by typing the name of the gene or any known alias
into the search box. The results of the search will be displayed in the left-hand panel, and the matching gene(s) will become
marked on the network (A). Phenotypes can be queried in the same way. The results of a phenotype search will display all
genes associated with the queried phenotype (B). Multiple phenotypes can be queried simultaneously by separating pheno-
types with a semicolon. The results of a multiple phenotype search will be displayed in different tabbed panels through which
the user can navigate (C). (D) Clicking on the gene’s submodel in any multiple phenotype search will display all highlighted
phenotypes from the query.
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Future Prospects
Due to its high success rate in predicting causative genes
by nonclinical testers, we conclude that the Leigh Map is
an efficacious diagnostic resource that, in combination
with WES data and metabolic testing, can be used by cli-
nicians to provide patients with accurate diagnoses or to
direct further biochemical investigation. Increased cer-
tainty of the genetic causes of mitochondrial disease has
significant implications, because it could potentially
attenuate the need for invasive diagnostic procedures,
namely muscle biopsy with an attendant general anes-
thetic, which could pose risk to pediatric patients. It is
important to iterate that we do not propose that the
Leigh Map act as a substitute for WES data or other rel-
evant functional studies, but rather as a supplement to
these techniques.
The computational nature of the Leigh Map allows
for the addition of novel disease genes or phenotypes
with relative ease; thereby, clinicians have access to a
database of all current causative genes, which can
enhance the interpretation of WES data. Ideally, we will
update both the phenotypic and genetic components of
the Leigh Map concurrently with the literature and also
develop a facility wherein experts can submit additional
genetic or phenotypic information. This is especially ben-
eficial within the context of mitochondrial diseases,
because novel genes are constantly being identified. For
Leigh syndrome specifically, one-third of the causative
genes were identified within the past 5 years.3
Currently, the most significant limitation of the
Leigh Map is the lack of a multiple advanced search
facility. Although the absence of this feature does not
detract from the network’s accuracy, it does reduce its
ease of use. Future work aims to implement this feature
into the network. Furthermore, the efficacy of the Leigh
Map is affected by the breadth of literature available for
individual genes. SURF1, one of the earliest mitochon-
drial disease genes to be identified and the most common
nuclear genetic cause of Leigh syndrome, is the subject
of numerous publications.19 Thus, SURF1 is associated
with> 90 phenotypes in the Leigh Map, the largest
number for any single gene. In contrast, the recently
characterized complex I assembly gene C17ORF8920 only
features in a small section of a larger publication and
accordingly is associated with only 2 phenotypes on the
Leigh Map, although patients who harbor this mutation
may display other phenotypes.
Expanding the current gene-to-phenotype binary of
the Leigh Map is a future prospect that can further
improve its usefulness as a diagnostic resource. Although
there are no current curative therapies for mitochondrial
disease, there are numerous compounds that are aimed at
symptomatic management, including anticonvulsant
drugs used to manage epilepsy and cofactor and vitamin
supplements, such as coenzyme Q10, thiamine, and bio-
tin, used to treat corresponding deficiencies. The addi-
tion of drug targets (a current feature of the MINERVA
platform) to the Leigh Map could potentially provide
insight into the effectiveness of various agents in treating
mitochondrial disease in specific genetic contexts. For
example, patients with SLC19A3 mutations respond dra-
matically to biotin and thiamine therapy,21 whereas those
with HIBCH mutations may benefit from N-acetyl cyste-
ine.22 cDNA and protein mutations and annotations
regarding animal models are also useful potential supple-
ments to the Leigh Map. Leigh syndrome is a defined
disorder5 wherein certain phenotypes appear almost ubiq-
uitously, including hypotonia (91% of patients), develop-
mental delay (82%), lactic acidosis (78%), and failure to
thrive (61%). The failure to deduce the correct candidate
genes for a minority of our test cases was due to the pre-
dominant presence of these common Leigh syndrome
phenotypes and a lack of discriminating phenotypes. We
found more success in "diagnosing" cases that presented
with less frequently observed phenotypes such as cardio-
myopathy (59%), optic atrophy (47%), or renal tubulop-
athy (15%). Therefore, the addition of these extra
elements can be helpful in narrowing down a large list of
candidate genes, thereby increasing the predictive power
of the Leigh Map. An alternative approach to increase
diagnostic power for common phenotypes is to incorpo-
rate a scoring system, which is a common element in
other bioinformatics resources such as BLAST.23 In the
context of our network, we propose "common" pheno-
types be scored lower than less frequently observed phe-
notypes. The addition of a scoring system would
complement the more sophisticated advanced search fea-
ture that we aim to implement in the future.
Progressive improvements in sequencing technolo-
gies and increased global cooperation have allowed for
the generation of copious amounts of genetic and clinical
information pertaining to mitochondrial disease. The
Leigh Map effectively integrates these clinical and scien-
tific data into an efficacious diagnostic resource for a
genetically heterogeneous disorder, the success of which
provides the basis for the construction of larger computa-
tional networks for a wider scope of mitochondrial and
metabolic diseases.
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